RNS Number : 3984B
Convatec Group PLC
02 November 2026

2 November 2026

Convatec Group Plc

("Convatec" or "the Company")

Total Voting Rights

In accordance with the UK Financial Conduct Authority's ("FCA") Disclosure and Transparency Rule 5.6.1R, the Company notifies the market that as at 30 October 2026:

1. The Company's issued share capital comprised 2,049,789,559 ordinary shares of 10 pence each, each with one vote.
2. 137,558,617 ordinary shares are held in treasury. These shares are not taken into consideration in relation to the payment of dividends and voting at shareholder meetings.

Accordingly, the total number of voting rights in the Company is 1,912,230,942. This figure may be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the FCA's Disclosure and Transparency Rules.

There are 11,774 ordinary shares of the Company which have been purchased pursuant to the share buyback programme announced on 4 August 2026 which are in the course of the settlement process. Once settled, these shares will be held in treasury.

Contacts

The person responsible for making this announcement is James Kerton, Company Secretary, Convatec Group Plc: cosec@convatec.com

Media: MediaRelations@convatec.com
Investor Relations: IR@convatec.com

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRMZMGMGZLGVZM